Get the Daily Brief
Latest Biotech News
Oral GLP-1 approval reshapes near-term obesity competition
Eli Lilly’s oral obesity drug Foundayo (orforglipron) won FDA approval, but the stock move quickly faded as investors weighed timing and competitive pricing versus Novo Nordisk’s oral Wegovy....
FDA volatility hits small biotech survival: Kezar shutdown
A four-month FDA delay forced Kezar Life Sciences to close its doors after the regulator canceled a key clinical-trial design meeting for an autoimmune hepatitis program. Kezar had reached an...
Cancer immunotherapy mechanism: glycocholic acid alters checkpoint response
Researchers reported that circulating glycocholic acid (GCA) can influence the efficacy of immune checkpoint therapies in colorectal cancer, pointing to a potential biomarker and combination...
Targeted AML combo signals in phase II
A phase II trial reported promising results for a combination of quizartinib and omacetaxine mepesuccinate in a high-risk AML setting. The study, published in Nature Communications in 2026,...
Drug–microbiome interaction affects Parkinson’s medication performance
A study published in Nature Microbiology reported that the gut microbiome can modulate the efficacy and safety of Parkinson’s disease medications, highlighting drug–microbiome interactions as a...
Oncology imaging: whole-body MRI forecasts ovarian cancer outcomes
Researchers reported that whole-body diffusion-weighted MRI (WB-DWI/MRI) can predict treatment outcomes for patients with advanced ovarian cancer following neoadjuvant chemotherapy. The findings,...
Regenerative/bioprocess innovation: nanotube injector enables cytoplasmic transfer
Waseda University researchers unveiled a nanotube membrane-based injector designed to transfer cytoplasmic contents between living cell populations with high viability. Published in Small Science,...
Capital raise for peptide drug development: Syneron Series B
Syneron Bio raised a $150 million Series B round to advance peptide programs built for improved drug-like properties, adding to its prior year fundraising efforts that totaled $100 million. The...
Oral GLP-1 competition heats up after FDA approval
Eli Lilly’s oral obesity drug Foundayo (orforglipron) won FDA authorization, but the initial market reaction cooled quickly as investors weighed sales ramp and pricing pressure. Shares rose the...
Small biotech shutdown highlights FDA review volatility risk
Kezar Life Sciences shut down after an FDA delay derailed a planned clinical trial-design meeting for its autoimmune hepatitis program. The company said the FDA agreed on a trial plan but only...
Funding boost for oral peptide platform targeting clinic-ready convenience
Pinnacle Medicines added $89 million to advance oral peptide drug candidates designed to combine biologic-like properties with small-molecule-style dosing. The startup says its lead program,...
Japan shows multi-decade rise in therapy-related acute myeloid leukemia
Population-based epidemiology in Japan reports an increase in therapy-related acute myeloid leukemia (tAML) over three decades, tying the trend to prior chemotherapy and radiation exposure. The...
Whole-body MRI moves into outcome prediction for advanced ovarian cancer
Researchers published data in the British Journal of Cancer suggesting whole-body diffusion-weighted MRI (WB-DWI/MRI) can predict treatment outcomes in advanced ovarian cancer after neoadjuvant...
Durvalumab plus tremelimumab tested in phase 2 for advanced thyroid cancer
The phase II GETNE-DUTHY trial reports on durvalumab plus tremelimumab in advanced thyroid carcinoma. The study evaluates the checkpoint inhibitor combination approach led by Capdevila and...
New target for colorectal immunotherapy: glycocholic acid blockade
A study describes circulating glycocholic acid (GCA) as a modulator of colorectal cancer response to immune checkpoint therapy, and reports that blocking GCA enhances immunotherapy efficacy. The...
V-ATPase highlighted in blastocyst cavitation using single-molecule embryo modeling
A research team introduced a single-small-molecule-based human embryo model to investigate blastocyst cavitation and identified V-ATPase as a key player in the process. The findings were published...
AI systems face clinical reality check on heart monitoring limitations
A commentary argues that algorithms flag arrhythmias but struggle with broader human context, using irregular heartbeat detection as an entry point. The piece emphasizes that recognizing...
NIH funding generates large economic returns while raising expectations for accountability
A research advocacy group, United for Medical Research, reports that NIH grant money stimulated the US economy with a measured economic return. The report also argues that certain NIH funding...
FDA delay that derailed Kezar’s autoimmune hepatitis trial and sale process
Kezar Life Sciences was forced to shut down after the FDA’s four-month delay in a key trial-design meeting arrived too late for its autoimmune hepatitis program. The company said it had reached an...
Oral GLP-1 approval sparks immediate market debate for Eli Lilly’s Foundayo
Eli Lilly’s oral GLP-1 obesity drug Foundayo (orforglipron) won FDA approval, but the initial stock reaction faded as analysts debated how fast prescriptions can build. The report said Lilly...